

with Mentat remarkably reduced oxidative stress and inflammation in the hippocampus, indicating that Mentat may have a protective effect on this brain region. Goyal *et al.*<sup>[37]</sup> in their study on the effect of Mentat on cognitive function and hippocampal neurogenesis in rats with seizures, revealed that treatment with Mentat significantly boosted hippocampus neurogenesis and improved cognitive performance in the rats, indicating that Mentat may benefit brain plasticity.

## Conclusion

The results of this study imply that Mentat has a protective effect against seizure-induced mice and may be employed in the control and treatment of seizures and other neurological diseases.

## Patient informed consent

There is no need for patient informed consent.

## Ethics committee approval

The Faculty of Basic Medical Sciences Committee on Animal Use and Care, University of Calabar, approved the use of experimental animals for this research project by the institution's established policies and procedures.

## Financial support and sponsorship

No funding was received.

## Conflict of interest

There is no conflict of interest to declare.

## Author Contributions subject and rate

- Ekpo Ubong Udeme (60%): Design the research, data collection, and analyses
- Igiri Anozeng Oyono (40%): Supervision and research organization.

## References

1. Fisher RS, Acevedo C, Arzimanoglou A, Bogacz A, Cross JH, Elger CE, *et al.* ILAE official report: A practical clinical definition of epilepsy. *Epilepsia* 2014;55:475-82. [doi: 10.1111/epi.12550].
2. World Health Organization. Epilepsy; 2019. Available from: <https://www.who.int/news-room/fact-sheets/detail/epilepsy>. [Last accessed on 2023 Mar 11].
3. Owolabi LF, Owolabi SD, Taura AA, Alhaji ID, Ogunniyi A. Prevalence and burden of epilepsy in Nigeria: A systematic review and meta-analysis of community-based door-to-door surveys. *Epilepsy Behav* 2019;92:226-34. [doi: 10.1016/j.yebeh.2018.11.035].
4. Engel J Jr., Pitkänen A, Loeb JA, Dudek FE, Bertram EH 3<sup>rd</sup>, Cole AJ, *et al.* Epilepsy biomarkers. *Epilepsia* 2013;54 Suppl 4:61-9. [doi: 10.1111/epi.12025].
5. Engel J, Pedley T. Epilepsy: A Comprehensive Textbook. 2<sup>nd</sup> ed. Philadelphia, USA: Lippincott Williams and Wilkins; 2008.
6. Scoville WB, Milner B. Loss of recent memory after bilateral hippocampal lesions. *J Neurol Neurosurg Psychiatry* 1957;20:11-21. [doi: 10.1136/jnnp.20.1.11].
7. Blümcke I, Thom M, Aronica E, Armstrong DD, Bartolomei F, Bernasconi A, *et al.* The clinicopathologic spectrum of focal epilepsies: A consensus report from the ILAE Task Force on Classification and Terminology. *Epilepsia* 2013;54:1-13. [doi: 10.1111/epi.12025].
8. Thom M, Liagkouras I, Martinian L, Liu J, Catarino CB, Sisodiya SM. Variability of sclerosis along the longitudinal hippocampal axis in epilepsy: A post mortem study. *Epilepsy Res* 2012;102:45-59. [doi: 10.1093/brain/aws226].
9. Balamurugan M, Srinivasan S, Thangarajan S. Epilepsy animal models. In: *Animal Models in Medicine and Biology*. Singapore: Springer; 2018. p. 301-18. [doi: 10.1007/978-981-10-8220-8\_14].
10. Pahuja R, Seth K, Shukla RK. Pentylenetetrazole-induced seizures: A review on experimental models. *World J Pharm Pharm Sci*. 2019;8:536-54.
11. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. *Epilepsia* 2006;47:1253-84. [doi: 10.1111/j.1528-1167.2011.03235.x].
12. Singh N, Bhalla M, de Jager P, Gilca M. An overview on ashwagandha: A Rasayana (rejuvenator) of Ayurveda. *Afr J Tradit Complement Altern Med* 2011;8:208-13. [doi: 10.4314/ajtcam.v8i5S.9].
13. Mathew J, Subramanian S. Evaluation of anticonvulsant and neurotoxic potential of *Bacopa monnieri* extract and its constituent bacoside-A in rats. *Epilepsy Behav* 2014;41:161-8. [doi: 10.1016/j.yebeh.2014.09.065].
14. Ahmad A, Ramasamy K, Jaafar SM, Majeed AB, Mani V. Protective effect of Mentat on pentylenetetrazole-induced seizures in rats. *BMC Complement Alternat Med* 2016;16:504. [doi: 10.1186/s12906-016-1503-3].
15. Tripathi M, Vibha D, Chaturvedi S, Sharma S, Singh S, Goyal V. Efficacy and safety of Mentat® in patients with epilepsy: A double-blind, randomized placebo-controlled, multicentric trial. *Epilepsy Behav* 2018;88:124-30. [doi: 10.1016/j.yebeh.2018.08.033].
16. Epilepsy Foundation. About Epilepsy.; 2021. Available from: <https://www.epilepsy.com/learn/about-epilepsy-and-seizures>. [Last accessed on 2023 Mar 11].
17. Engel J Jr., Pedley TA, editors. *Epilepsy: A Comprehensive Textbook*. 2<sup>nd</sup> ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams and Wilkins; 2008. [doi: 10.1097/01.nrl.0000315420.09785.d6].
18. Jung ME, Lal H, Gatch MB. The discriminative stimulus effects of pentylenetetrazol as a model of anxiety: Recent developments. *Neurosci Biobehav Rev* 2002;26:429-39. [doi: 10.1016/s0149-7634(02)00010-8].
19. Bhattacharya SK. Evaluation of adaptogenic activity of Trasina, an ayurvedic herbal formulation. In: Mukherjee B. (Ed). *Traditional medicine*. Oxford and IBH Publishers, New Delhi, 1993:320.
20. Perucca P, Gilliam FG, Adinolfi LE. Antiepileptic drugs: Current and future strategies. *Epileptic Disord* 2018;20:249-61. [doi: 10.1684/epd.2018.1000].
21. Bhattacharya SK, Kumar A. Effect of *Bacopa monniera* on animal models of epilepsy and behavior. *J Ethnopharmacol* 2007;111:671-6. [doi: 10.1016/j.jep.2007.01.007].
22. Kulkarni SK, George B. Antidepressant-like activity of the novel water-soluble polymer entrapped BR-16A (Mentat®). *Pharmacol Biochem Behav* 2006;83:135-40. [doi: 10.1016/j.pbb.2005.12.015].
23. Choudhary M, Kumar V, Malhotra H, Singh S, Kumar V. Antiepileptic potential of Mentat, a polyherbal preparation, in Wistar rats. *J Ayurveda Integr Med* 2016;7:21-7. [doi: 10.1016/j.jaim.2016.03.001].

- jaim.2015.07.004].
24. Singh RH, Singh L, Sharma P. Evaluation of the antiepileptic activity of Mentat, a polyherbal formulation. Indian J Physiol Pharmacol 2008;52:285-93. [doi: 10.1016/j.yebeh.2018.08.033].
  25. Kulkarni SK, Dhir A, Agarwal A. Evaluation of the anticonvulsant and antioxidant activity of Mentat in pentylenetetrazole-induced kindling in mice. Indian J Physiol Pharmacol 2010;54:256-64. [doi: 10.1016/j.yebeh.2018.08.033].
  26. Mohan M, Jaiswal AK, Singh VK. Evaluation of the anticonvulsant and antioxidant effect of Mentat, a polyherbal formulation, in the pentylenetetrazole-induced kindling model of epilepsy in rats. Indian J Pharmacol 2010;46:423-7. [doi: 10.4103/0253-7613.68422].
  27. Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004;73:1-60. [doi: 10.1016/j.pneurobio.2004.03.009].
  28. Chen K, Chen G, Chen Z, Wu D, Feng J, Chen Y. Pentylenetetrazol-induced hippocampal apoptosis involves down-regulation of Bcl-2 and activation of caspase-3. Neurosci Lett 2010;470:98-102. [doi: 10.1016/j.neulet.2009.12.063].
  29. Sinha S, Patil SA, Jayalekshmy V, Satishchandra P. Do cytokines have any role in epilepsy? Epilepsy Res 2008;82:171-6. [doi: 10.1016/j.eplepsyres.2008.08.003].
  30. Liu YQ, Yu JL, Zhang XJ, Zhang QB, Wang YJ. Protective effect of gallic acid on pentylenetetrazol-induced acute seizure and chronic epilepsy via oxidative stress. Biomed Pharmacother 2018;108:1682-9. [doi: 10.1016/j.biopharm.2018.09.078].
  31. Wang J, Li M, Wang Q, Zhao J, Liang G. Pentylenetetrazol-induced epileptic seizures enhance dendritic spine density and spine head width in CA1 pyramidal neurons of rat hippocampal slices. Brain Res 2014;1581:83-90. [doi: 10.1016/j.brainres.2014.07.032].
  32. Wang J, Liu L, Zhao J, Li M, Liang G. Effects of pentylenetetrazol-induced epileptic seizure on dendritic spine distribution in hippocampal CA3 pyramidal neurons of rats. Neurol Res 2015;37:457-64. [doi: 10.1179/1743132815Y.0000000008].
  33. Wasterlain CG, Thompson KW, Kupferberg HJ. Pentylenetetrazol-induced seizures: time-course of EEG and behavioral tolerance and changes in GABA-mediated inhibition and the effect of clonazepam and phenobarbital. Electroencephalogr Clin Neurophysiol 1982;54:603-12. [doi: 10.1016/0013-4694(82)90086-8].
  34. Löscher W, Schmidt D. Experimental and clinical evidence for loss of effect (tolerance) during prolonged treatment with antiepileptic drugs. Epilepsia 2006;47:1253-84. [doi: 10.1111/j.1528-1167.2006.00644.x].
  35. Mohan M, Soni P, Goyal R, Singh M. Ameliorative effect of Mentat on seizure-induced hippocampal damage in rats. J Complement Integr Med 2014;11):99-106. [doi: 10.1515/jcim-2013-0035].
  36. Al-Otaibi AF, Al-Harthi SE, Al-Rejaie SS, Al-Bakheet SA. Protective effect of Mentat® against oxidative stress and inflammation in the hippocampus of rats with seizures. Biomed Pharmacother 2019;111:947-53. [doi: 10.1016/j.biopharm.2018.12.022].
  37. Goyal PK, Singh A, Kumar A. Effect of Mentat on cognitive function and hippocampal neurogenesis in rats with seizures. Pharmacogn Res 2016;8:51-6. [doi: 10.4103/0974-8490.171096].